Keytruda®

Active substance

Pembrolizumab - MK 3475

Holder

MSD

Status

Closed

Indication

In combination with chemotherapy (carboplatin + paclitaxel) for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 with a tumour proportion score (TPS) between l%-49% or no PD-L1 (TPS <1%).

Public documents

Approbation

Information for the patient

Informed consent

Dernière mise à jour

04/04/2019

Last updated on 13/02/2024